20826-03-3

Basic information

• Product Name: 5-METHOXY-NICOTINIC ACID
• Synonyms: 5-Methoxynicotinic acid;3-Methoxy-5-pyridinecarboxylic acid;3-Methoxypyridine-5-carboxylic acid;5-Methoxypyridine-3-carboxylic acid, 3-Carboxy-5-methoxypyridine
• CAS NO: 20826-03-3
• Molecular Formula: C₇H₇NO₃
• Molecular Weight: 153.13
• Product Categories: Carboxylic Acids;Pyridines
• Mol File: 20826-03-3.mol
• Article Data: 5

Chemical Properties

• Melting Point: 127-131°C
• Boiling Point: 330.9oC at 760 mmHg
• Flash Point: 154oC
• Appearance: /
• Density: 1.284g/cm3
• Vapor Pressure: 6.43E-05mmHg at 25°C
• Refractive Index: 1.549
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 2.08±0.10(Predicted)
• CAS DataBase Reference: 5-METHOXY-NICOTINIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHOXY-NICOTINIC ACID(20826-03-3)
• EPA Substance Registry System: 5-METHOXY-NICOTINIC ACID(20826-03-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 20826-03-3(Hazardous Substances Data)

Usage

General Description

5-Methoxy-Nicotinic Acid, also known as 5-Methoxy-pyridine-3-carboxylic acid, is a derivative of nicotinic acid, which is a form of vitamin B3 or niacin. Its molecular formula is C7H7NO3. As an organonitrogen compound, it contains a carboxylic acid group and a methoxy group attached to a pyridine ring. However, its biological and pharmacological properties remain largely under research. Currently, there are no specific details about its immediate role in health and disease, making it typically referenced in the context of chemical compounds and scientific experiments. The chemical's safety profile, usage, and handling procedures should be determined by referring to relevant standard guides and material safety data sheets.

InChI:InChI=1/C7H7NO3/c1-11-6-2-5(7(9)10)3-8-4-6/h2-4H,1H3,(H,9,10)

Upstream product

• 29681-46-7 methyl 5-methoxypyridine-3-carboxylate 
• 124-38-9 carbon dioxide 
• 109345-94-0 3-hydroxy-5-methoxypyridine 
• 30766-22-4 methyl 5-hydroxy-3-pyridinecarboxylate 

Downstream Products

• 29681-46-7 methyl 5-methoxypyridine-3-carboxylate 
• 177661-64-2 3-methoxy-5-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine 
• 298204-74-7 5-(methyloxy)pyridine-3-carbonitrile 

Relevant articles and documents

Nickel-catalyzed carboxylation of aryl and heteroaryl fluorosulfates using carbon dioxide

The development of efficient and practical methods to construct carboxylic acids using CO2 as a C1 synthon is of great importance. Nickel-catalyzed carboxylation of aryl fluorosulfates and heteroaryl fluorosulfates with CO2 is described, affording arene carboxylic acids with good to excellent yields under mild conditions. In addition, a one-pot phenol fluorosulfation/carboxylation is developed.

PYRROLOPYRIDAZINE DERIVATIVES

The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-α mediated diseases.

Selective cyclooxygenase-2 inhibitors: Heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents

A series of heteroaryl modified 1,2-diarylimidazoles has been synthesized and found to be potent and highly selective (1000-9000-fold) inhibitors of the human COX-2.3-Pyridyl derived COX-2 selective inhibitor (25) exhibited excellent activity in acute (carrageenan induced paw edema, ED50 = 5.4 mg/kg) and chronic (adjuvant induced arthritis, ED50 = 0.25 mg/kg) models of inflammation. The relatively long half-life of 25 in rat and dog prompted investigation of the pyridyl and other heteroaromatic systems containing potential metabolic functionalities. A number of substituted pyridyl and thiazole containing compounds (e.g., 44, 46, 54, 76, and 78) demonstrated excellent oral activity in every efficacy model evaluated. Several orally active diarylimidazoles exhibited desirable pharmacokinetics profiles and showed no GI toxicity in the rat up to 100 mg/kg in both acute and chronic models. The paper describes facile and practical syntheses of the targeted diarylimidazoles. The structure-activity relationships and antiinflammatory properties of a series of diarylimidazoles are discussed.